Sugi Predict

Sugi Predict / Compounds / SCHEMBL2501419

SCHEMBL2501419

SCHEMBL2501419

COC(=O)CC(c1cccc(O)c1)C1CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 2/20 0.48
▸ OPRK1 P41145 2/20 0.48
▸ FFAR1 O14842 7/20 0.43
▸ HIF1A Q16665 3/20 0.40
▸ ADRB2 P07550 1/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ADRA2B P18089 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ DRD1 P21728 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADRA1B P35368 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454615 1.00 OPRD1 (0.48) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL2504416 1.00 OPRD1 (0.48) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL2495215 1.00 OPRD1 (0.48) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL30533375 1.00 OPRD1 (0.48) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL29454583 1.00 OPRD1 (0.48) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL2497736 0.95 OPRD1 (0.46) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL15972566 0.95 OPRD1 (0.46) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL2498866 0.95 OPRD1 (0.46) OPRD1OPRK1FFAR1HIF1AADRB2
SCHEMBL17428343 0.86 OPRD1 (0.44) OPRD1OPRK1FFAR1
SCHEMBL17418579 0.86 OPRD1 (0.44) OPRD1OPRK1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2958562-B1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC (US) 2025-09-10 — — EP disclosed
US-20240002354-A1 ANTIDIABETIC COMPOUNDS AND COMPOSITIONS REZUBIO PHARMACEUTICALS CO., LTD (CN) 2024-01-04 — — US disclosed
US-20220226298-A1 GPR40 AGONISTS KALLYOPE, INC. 2022-07-21 — — US disclosed
EP-3976576-A1 GPR40 AGONISTS Kallyope, Inc. (US) 2022-04-06 — — EP disclosed
CN-108017603-B Tricyclic compounds and uses thereof 株式会社蒂奥姆生物 2021-07-23 — — CN disclosed
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2021-04-27 — — US disclosed
WO-2020242943-A1 GPR40 AGONISTS KALLYOPE, INC. (US) 2020-12-03 — — WO disclosed
EP-3102198-B1 ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME (US) 2020-08-26 — — EP disclosed
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN RESEARCH & DEVELOPMENT, LLC 2020-02-06 — — US disclosed
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 — — EP disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 — — US disclosed
CN-102083783-A Substituted biphenyl GPR40 modulators AMGEN INC 2011-06-01 — — CN disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 — — EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 — — US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 — — WO disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 OPRD1 852/4885OPRK1 557/4885FFAR1 18/4885
US-20220226298-A1 GPR40 AGONISTS GPR119, GPR65, GLP1R OPRD1 447/4885OPRK1 185/4885FFAR1 10/4885
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GPR65, GPR55 OPRD1 515/4885OPRK1 378/4885FFAR1 16/4885
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes GPR119, GPR65, GPR55 OPRD1 515/4885OPRK1 378/4885FFAR1 16/4885
US-20240002354-A1 ANTIDIABETIC COMPOUNDS AND COMPOSITIONS GPR119, GLP1R, GPR65 OPRD1 999/4885OPRK1 800/4885FFAR1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.